- Home
- SPRO vs CNTY Comparison
SPRO vs CNTY Comparison
Compare SPRO & CNTY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPRO
- CNTY
- Stock Information
- Founded
- SPRO 2013
- CNTY 1992
- Country
- SPRO United States
- CNTY United States
- Employees
- SPRO N/A
- CNTY N/A
- Industry
- SPRO Biotechnology: Pharmaceutical Preparations
- CNTY Hotels/Resorts
- Sector
- SPRO Health Care
- CNTY Consumer Discretionary
- Exchange
- SPRO Nasdaq
- CNTY Nasdaq
- Market Cap
- SPRO 164.4M
- CNTY 75.2M
- IPO Year
- SPRO 2017
- CNTY 1993
- Fundamental
- Price
- SPRO $2.90
- CNTY $2.16
- Analyst Decision
- SPRO Buy
- CNTY Strong Buy
- Analyst Count
- SPRO 4
- CNTY 6
- Target Price
- SPRO $5.00
- CNTY $5.00
- AVG Volume (30 Days)
- SPRO 1.8M
- CNTY 68.0K
- Earning Date
- SPRO 08-04-2025
- CNTY 08-07-2025
- Dividend Yield
- SPRO N/A
- CNTY N/A
- EPS Growth
- SPRO N/A
- CNTY N/A
- EPS
- SPRO N/A
- CNTY N/A
- Revenue
- SPRO $44,584,000.00
- CNTY $570,345,000.00
- Revenue This Year
- SPRO N/A
- CNTY $4.58
- Revenue Next Year
- SPRO N/A
- CNTY $6.53
- P/E Ratio
- SPRO N/A
- CNTY N/A
- Revenue Growth
- SPRO N/A
- CNTY N/A
- 52 Week Low
- SPRO $0.51
- CNTY $1.30
- 52 Week High
- SPRO $3.09
- CNTY $5.09
- Technical
- Relative Strength Index (RSI)
- SPRO 71.31
- CNTY 52.66
- Support Level
- SPRO $2.79
- CNTY $1.96
- Resistance Level
- SPRO $3.09
- CNTY $2.38
- Average True Range (ATR)
- SPRO 0.15
- CNTY 0.18
- MACD
- SPRO -0.07
- CNTY -0.03
- Stochastic Oscillator
- SPRO 57.78
- CNTY 39.68
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
About CNTY Century Casinos Inc.
Century Casinos Inc is a casino entertainment company that develops and operates gaming establishments as well as related lodging, restaurants, horse racing (including off-track betting), and entertainment facilities in North America. The company has three reportable segments based on the geographical locations in which its casinos operate; United States; Century Casino & Hotel-Central City, and Century Casino & Hotel-Cripple Creek in Colorado, Mountaineer Casino, Racetrack & Resort in West Virginia, and Century Casino Caruthersville, and Century Casino Cape Girardeau in Missouri, Canada; Century Casino & Hotel, Century Casino St. Albert, Century Mile Racetrack in Edmonton and Casino Century Downs Racetrack and Casino in Calgary, and Poland; Casinos Poland.